Cargando…

Identification and Validation of FGF-Related Prognostic Signatures in Prostate Cancer

BACKGROUND: FGF signaling is critical to controlling various cancers. Nevertheless, the functions of FGF-related genes in PCa are still unknown. OBJECTIVE: The objective of this study is to build a FGF-related signature that was capable of accurately predicting PCa survival and prognosis for BCR. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Yongkang, Mo, Rujun, Zheng, Ruinian, Zou, Jun, Liu, Shaoqian, Mi, Qiwu, Zhong, Weide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974262/
https://www.ncbi.nlm.nih.gov/pubmed/36865499
http://dx.doi.org/10.1155/2023/7342882
_version_ 1784898690572353536
author Ye, Yongkang
Mo, Rujun
Zheng, Ruinian
Zou, Jun
Liu, Shaoqian
Mi, Qiwu
Zhong, Weide
author_facet Ye, Yongkang
Mo, Rujun
Zheng, Ruinian
Zou, Jun
Liu, Shaoqian
Mi, Qiwu
Zhong, Weide
author_sort Ye, Yongkang
collection PubMed
description BACKGROUND: FGF signaling is critical to controlling various cancers. Nevertheless, the functions of FGF-related genes in PCa are still unknown. OBJECTIVE: The objective of this study is to build a FGF-related signature that was capable of accurately predicting PCa survival and prognosis for BCR. METHODS: The univariate and multivariate Cox regression, infiltrating immune cells, LASSO, and GSEA analyses were carried out to build a prognostic model. RESULTS: A FGF-related signature that consists of PIK3CA and SOS1 was developed for the purpose of predicting PCa prognosis, and all patients were categorized into low- and high-risk groups. In comparison to the low-risk group, high-risk score patients had poorer BCR survival. This signature's predictive power has been investigated utilizing the AUC of the ROC curves. The risk score has been shown to be an independent prognostic factor by multivariate analysis. The four enriched pathways of the high-risk group were obtained by gene set enrichment analysis (GSEA) and found to be associated with the tumorigenesis and development of PCa, including focal adhesion, TGF-β signaling pathway, adherens junction, and ECM receptor interaction. The high-risk groups had considerably higher levels of immune status and tumor immune cell infiltration, suggesting a more favorable response to immune checkpoint inhibitors. IHC found that the expression of the two FGF-related genes in the predictive signature was extremely different in PCa tissues. CONCLUSION: To summarize, our FGF-related risk signature may effectively predict and diagnose PCa, indicating that in PCa patients, they are potential therapeutic targets and promising prognostic biomarkers.
format Online
Article
Text
id pubmed-9974262
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-99742622023-03-01 Identification and Validation of FGF-Related Prognostic Signatures in Prostate Cancer Ye, Yongkang Mo, Rujun Zheng, Ruinian Zou, Jun Liu, Shaoqian Mi, Qiwu Zhong, Weide Dis Markers Research Article BACKGROUND: FGF signaling is critical to controlling various cancers. Nevertheless, the functions of FGF-related genes in PCa are still unknown. OBJECTIVE: The objective of this study is to build a FGF-related signature that was capable of accurately predicting PCa survival and prognosis for BCR. METHODS: The univariate and multivariate Cox regression, infiltrating immune cells, LASSO, and GSEA analyses were carried out to build a prognostic model. RESULTS: A FGF-related signature that consists of PIK3CA and SOS1 was developed for the purpose of predicting PCa prognosis, and all patients were categorized into low- and high-risk groups. In comparison to the low-risk group, high-risk score patients had poorer BCR survival. This signature's predictive power has been investigated utilizing the AUC of the ROC curves. The risk score has been shown to be an independent prognostic factor by multivariate analysis. The four enriched pathways of the high-risk group were obtained by gene set enrichment analysis (GSEA) and found to be associated with the tumorigenesis and development of PCa, including focal adhesion, TGF-β signaling pathway, adherens junction, and ECM receptor interaction. The high-risk groups had considerably higher levels of immune status and tumor immune cell infiltration, suggesting a more favorable response to immune checkpoint inhibitors. IHC found that the expression of the two FGF-related genes in the predictive signature was extremely different in PCa tissues. CONCLUSION: To summarize, our FGF-related risk signature may effectively predict and diagnose PCa, indicating that in PCa patients, they are potential therapeutic targets and promising prognostic biomarkers. Hindawi 2023-02-21 /pmc/articles/PMC9974262/ /pubmed/36865499 http://dx.doi.org/10.1155/2023/7342882 Text en Copyright © 2023 Yongkang Ye et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ye, Yongkang
Mo, Rujun
Zheng, Ruinian
Zou, Jun
Liu, Shaoqian
Mi, Qiwu
Zhong, Weide
Identification and Validation of FGF-Related Prognostic Signatures in Prostate Cancer
title Identification and Validation of FGF-Related Prognostic Signatures in Prostate Cancer
title_full Identification and Validation of FGF-Related Prognostic Signatures in Prostate Cancer
title_fullStr Identification and Validation of FGF-Related Prognostic Signatures in Prostate Cancer
title_full_unstemmed Identification and Validation of FGF-Related Prognostic Signatures in Prostate Cancer
title_short Identification and Validation of FGF-Related Prognostic Signatures in Prostate Cancer
title_sort identification and validation of fgf-related prognostic signatures in prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974262/
https://www.ncbi.nlm.nih.gov/pubmed/36865499
http://dx.doi.org/10.1155/2023/7342882
work_keys_str_mv AT yeyongkang identificationandvalidationoffgfrelatedprognosticsignaturesinprostatecancer
AT morujun identificationandvalidationoffgfrelatedprognosticsignaturesinprostatecancer
AT zhengruinian identificationandvalidationoffgfrelatedprognosticsignaturesinprostatecancer
AT zoujun identificationandvalidationoffgfrelatedprognosticsignaturesinprostatecancer
AT liushaoqian identificationandvalidationoffgfrelatedprognosticsignaturesinprostatecancer
AT miqiwu identificationandvalidationoffgfrelatedprognosticsignaturesinprostatecancer
AT zhongweide identificationandvalidationoffgfrelatedprognosticsignaturesinprostatecancer